Circular RNA Therapeutics in 2025: Transforming RNA Medicine with Breakthroughs in Stability, Delivery, and Disease Targeting. Explore the Market Forces and Innovations Shaping the Next Five Years.
- Executive Summary: Circular RNA Therapeutics Market Outlook 2025–2030
- Technology Overview: Mechanisms and Advantages of Circular RNA
- Key Players and Strategic Partnerships (e.g., circRNApharma.com, rnatx.com)
- Current Clinical Pipeline and Regulatory Milestones
- Market Size, Segmentation, and 2025–2030 Growth Forecasts (Estimated CAGR: 38–45%)
- Manufacturing Innovations and Scalability Challenges
- Therapeutic Applications: Oncology, Rare Diseases, and Beyond
- Competitive Landscape and Intellectual Property Trends
- Investment, Funding, and M&A Activity
- Future Outlook: Opportunities, Risks, and Next-Generation Developments
- Sources & References
Executive Summary: Circular RNA Therapeutics Market Outlook 2025–2030
The circular RNA (circRNA) therapeutics market is poised for significant transformation between 2025 and 2030, driven by rapid advances in RNA biology, innovative delivery technologies, and increasing investment from both established pharmaceutical companies and specialized biotechnology firms. CircRNAs, characterized by their covalently closed loop structures, offer unique advantages over linear RNAs, including enhanced stability, resistance to exonucleases, and the potential for novel mechanisms of action. These properties have positioned circRNAs as promising candidates for next-generation therapeutics, particularly in areas such as oncology, rare genetic disorders, and immunotherapy.
As of 2025, the field is transitioning from preclinical exploration to early-stage clinical development. Several biotechnology companies are at the forefront of this movement. Orna Therapeutics, a pioneer in the space, has developed proprietary circular RNA expression platforms and is advancing a pipeline of circRNA-based therapeutics targeting cancer and genetic diseases. In 2023, Orna announced a strategic collaboration with Merck & Co., Inc. (MSD) to develop and commercialize novel circRNA vaccines and therapeutics, with the partnership valued at up to $3.5 billion in potential milestones. This collaboration underscores the growing confidence of major pharmaceutical players in the therapeutic potential of circRNAs.
Another notable player, Lantern Pharma, is leveraging artificial intelligence to identify and optimize circRNA candidates for oncology indications. Meanwhile, Aarna Therapeutics is focusing on the development of circRNA-based therapies for neurodegenerative diseases and rare disorders, with several programs in preclinical stages as of 2025.
The next few years are expected to witness the initiation of first-in-human clinical trials for circRNA therapeutics, particularly in oncology and vaccine applications. The robust stability and translational efficiency of circRNAs make them attractive for mRNA replacement therapies and as platforms for protein expression. Additionally, advances in delivery technologies—such as lipid nanoparticles and targeted delivery systems—are addressing key challenges related to the efficient and safe administration of circRNA drugs.
Regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, are beginning to engage with developers to establish guidelines for the clinical evaluation of circRNA-based products. This regulatory clarity is anticipated to accelerate clinical development and facilitate market entry.
Overall, the outlook for the circRNA therapeutics market from 2025 to 2030 is highly promising. The sector is expected to attract increasing investment, witness the emergence of new entrants, and see the first clinical proof-of-concept data. If early clinical trials validate the safety and efficacy of circRNA therapeutics, the market could experience rapid expansion, with the potential to reshape the landscape of RNA-based medicine.
Technology Overview: Mechanisms and Advantages of Circular RNA
Circular RNA (circRNA) therapeutics represent a rapidly advancing frontier in RNA-based medicine, leveraging the unique structural and functional properties of covalently closed RNA molecules. Unlike linear messenger RNA (mRNA), circRNAs form continuous loops without 5’ or 3’ ends, conferring them with exceptional stability against exonuclease-mediated degradation. This intrinsic stability is a key technological advantage, enabling prolonged protein expression and reducing the frequency of dosing in therapeutic applications.
Mechanistically, circRNAs can be engineered to encode therapeutic proteins or peptides, functioning as templates for translation in target cells. Their circular structure not only enhances resistance to cellular nucleases but also supports efficient ribosome recruitment and translation, especially when optimized with internal ribosome entry sites (IRES) or N6-methyladenosine (m6A) modifications. This results in robust and sustained protein production, a critical requirement for many therapeutic indications.
In 2025, several biotechnology companies are advancing circRNA platforms for diverse therapeutic areas. Orna Therapeutics is a prominent leader, having developed proprietary “oRNA” circular RNA constructs designed for in vivo delivery and durable protein expression. Their technology is being applied to oncology, genetic diseases, and vaccines, with preclinical and early clinical data demonstrating superior stability and expression compared to traditional mRNA approaches. Another key player, Laronde, is pioneering the Endless RNA™ (eRNA) platform, which utilizes synthetic circRNAs to enable repeatable and tunable protein production, aiming to address chronic diseases with a single administration.
The advantages of circRNA therapeutics extend beyond stability and expression. CircRNAs exhibit reduced immunogenicity relative to linear mRNA, minimizing the risk of adverse immune responses and enabling repeated dosing. Their compact and modular design allows for the incorporation of multiple functional elements, such as tissue-specific targeting motifs or regulatory sequences, enhancing therapeutic precision. Additionally, the manufacturing processes for circRNAs are being optimized for scalability and cost-effectiveness, with companies like Orna Therapeutics and Laronde investing in robust production pipelines to support clinical and commercial supply.
Looking ahead, the next few years are expected to see the first clinical proof-of-concept data for circRNA therapeutics, particularly in oncology and rare genetic disorders. The field is also exploring combination strategies with lipid nanoparticle (LNP) delivery systems, as seen in partnerships between circRNA innovators and established RNA delivery companies. As the technology matures, circRNA therapeutics are poised to complement or surpass existing mRNA modalities, offering new solutions for diseases with unmet medical needs.
Key Players and Strategic Partnerships (e.g., circRNApharma.com, rnatx.com)
The field of circular RNA (circRNA) therapeutics is rapidly evolving, with 2025 marking a pivotal year for both established biotechnology firms and emerging startups. The sector is characterized by a surge in strategic partnerships, licensing agreements, and investments aimed at accelerating the development and commercialization of circRNA-based medicines. These collaborations are essential for overcoming technical challenges, scaling manufacturing, and navigating regulatory pathways.
Among the most prominent players is Circular RNA Pharma, a company dedicated exclusively to the discovery and development of circRNA therapeutics. Circular RNA Pharma has established a robust pipeline targeting rare genetic diseases and oncology, leveraging proprietary circularization technologies to enhance RNA stability and translational efficiency. In 2024, the company announced a strategic partnership with a leading contract development and manufacturing organization (CDMO) to scale up GMP-grade circRNA production, positioning itself for first-in-human clinical trials in 2025.
Another key innovator is RNA Tx, which focuses on the design and delivery of synthetic circRNAs for protein replacement therapies. RNA Tx has entered into multiple research collaborations with academic institutions and pharmaceutical companies to expand its platform applications. In early 2025, RNA Tx secured a multi-million dollar investment round to accelerate preclinical development and expand its intellectual property portfolio, signaling strong investor confidence in the therapeutic potential of circRNAs.
Large pharmaceutical companies are also entering the circRNA space through partnerships and in-house R&D. For example, Roche has publicly disclosed its interest in RNA-based modalities, including circRNAs, and is actively seeking collaborations with biotech firms to co-develop next-generation RNA therapeutics. Similarly, Bayer has expanded its RNA innovation hub to include circRNA research, aiming to integrate these molecules into its broader gene and cell therapy portfolio.
Strategic alliances are not limited to drug development. Manufacturing and delivery remain critical bottlenecks, prompting companies like Evotec to offer specialized services for circRNA synthesis and formulation. These partnerships are expected to play a crucial role in enabling clinical translation and eventual commercialization.
Looking ahead, the next few years will likely see further consolidation and cross-sector collaboration as the circRNA therapeutics landscape matures. The entry of major pharmaceutical players, combined with the agility of specialized biotech firms, is expected to accelerate the path toward clinical validation and regulatory approval, potentially making circRNA-based medicines a reality by the late 2020s.
Current Clinical Pipeline and Regulatory Milestones
The clinical pipeline for circular RNA (circRNA) therapeutics has expanded rapidly as of 2025, with several candidates advancing from preclinical proof-of-concept to early-stage human trials. CircRNAs, characterized by their covalently closed loop structures, offer enhanced stability and translational efficiency compared to linear mRNA, making them attractive for therapeutic applications such as protein replacement, vaccines, and gene modulation.
Among the leaders in this space, Orna Therapeutics has emerged as a pioneer, leveraging its proprietary oRNA™ technology to develop circular RNA-based medicines. In 2023, Orna announced the initiation of its first-in-human clinical trial for ORN-101, a circRNA therapeutic targeting solid tumors by encoding a bispecific T cell engager. This Phase 1 trial represents a significant regulatory milestone, as it is among the first circRNA-based therapies to enter human testing. Orna’s pipeline also includes candidates for autoimmune diseases and genetic disorders, with additional IND filings anticipated in 2025 and beyond.
Another notable player, Laronde, is advancing its Endless RNA™ (eRNA) platform, which utilizes engineered circRNAs for programmable protein expression. Laronde has disclosed multiple preclinical programs in rare diseases, oncology, and vaccines, and has announced plans to initiate clinical trials in 2025. The company’s collaborations with major pharmaceutical partners underscore the growing industry confidence in circRNA modalities.
In the vaccine arena, Moderna has publicly stated its interest in circRNA as a next-generation platform, building on its mRNA expertise. In 2023, Moderna presented preclinical data demonstrating the superior durability and immunogenicity of circRNA vaccines compared to linear mRNA, and has indicated that clinical development could commence within the next few years. Similarly, BioNTech is actively exploring circRNA for both cancer immunotherapy and infectious disease vaccines, with preclinical candidates progressing toward regulatory submission.
Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are closely monitoring these developments. In 2024, the FDA granted Orna Therapeutics an Investigational New Drug (IND) clearance for its lead candidate, setting a precedent for circRNA-based products. As more companies file INDs and initiate trials, regulatory frameworks are expected to evolve, with guidance on manufacturing, quality control, and safety assessment tailored to the unique properties of circRNA.
Looking ahead, the next few years will be pivotal for the field. Multiple first-in-human studies are expected to yield initial safety and efficacy data, which will inform the broader adoption and regulatory acceptance of circRNA therapeutics. The sector’s momentum is further supported by significant venture investment and strategic partnerships, positioning circRNA as a transformative modality in the RNA therapeutics landscape.
Market Size, Segmentation, and 2025–2030 Growth Forecasts (Estimated CAGR: 38–45%)
The global market for circular RNA (circRNA) therapeutics is poised for rapid expansion between 2025 and 2030, with estimated compound annual growth rates (CAGR) ranging from 38% to 45%. This surge is driven by accelerating preclinical and early clinical developments, increasing investment from both established pharmaceutical companies and specialized biotechnology firms, and the growing recognition of circRNA’s unique therapeutic potential compared to linear RNA modalities.
As of 2025, the circRNA therapeutics market remains in its nascent stage, with most candidates in preclinical or early-phase clinical trials. However, the sector is witnessing significant segmentation across therapeutic areas, delivery technologies, and application types. Oncology leads as the primary focus, with companies such as Orna Therapeutics and Lantern Pharma advancing circRNA-based candidates targeting solid tumors and hematological malignancies. Beyond cancer, there is growing interest in rare genetic disorders, infectious diseases, and regenerative medicine, reflecting the versatility of circRNA platforms.
The market is also segmented by delivery technologies, with lipid nanoparticles (LNPs) dominating as the preferred vehicle for circRNA delivery, mirroring trends seen in mRNA therapeutics. Companies like Orna Therapeutics have established proprietary LNP systems optimized for circRNA stability and cellular uptake. Additionally, partnerships between circRNA developers and established delivery technology providers are expected to proliferate, further accelerating market growth.
Geographically, North America is anticipated to maintain a leading position through 2030, driven by robust R&D infrastructure, favorable regulatory environments, and the presence of pioneering firms such as Orna Therapeutics and Lantern Pharma. Europe and Asia-Pacific are also emerging as important regions, with increasing investment in circRNA research and early-stage company formation.
Looking ahead, the circRNA therapeutics market is projected to reach multi-billion-dollar valuations by 2030, contingent on successful clinical translation and regulatory approvals. The anticipated CAGR of 38–45% reflects both the low current revenue base and the high unmet need in target indications. Key growth drivers include the scalability of circRNA manufacturing, expanding intellectual property portfolios, and the potential for circRNA to address limitations of existing RNA-based drugs, such as improved stability and reduced immunogenicity.
- Key players: Orna Therapeutics (Boston-based, leading circRNA platform developer), Lantern Pharma (Texas-based, oncology-focused circRNA R&D), and emerging entrants in the US, Europe, and Asia-Pacific.
- Therapeutic focus: Oncology, rare diseases, infectious diseases, regenerative medicine.
- Delivery technologies: Lipid nanoparticles (LNPs), novel nanoparticle systems.
- Growth drivers: Clinical trial initiations, strategic partnerships, manufacturing scale-up, and regulatory milestones.
Overall, the next five years are expected to be transformative for the circRNA therapeutics market, with rapid growth, increasing segmentation, and the potential for the first regulatory approvals by the end of the decade.
Manufacturing Innovations and Scalability Challenges
The rapid emergence of circular RNA (circRNA) therapeutics is driving significant innovation in manufacturing processes, as the sector moves from early-stage research to clinical and commercial-scale production. In 2025, the primary focus is on overcoming scalability challenges, ensuring product consistency, and meeting stringent regulatory requirements for advanced RNA modalities.
Unlike linear mRNA, circRNAs are covalently closed loops, conferring enhanced stability and resistance to exonucleases. However, these unique structural features also complicate large-scale synthesis and purification. Traditional in vitro transcription (IVT) methods, widely used for mRNA, require adaptation for efficient circRNA production. Key industry players are investing in proprietary enzymatic ligation and ribozyme-mediated circularization techniques to improve yield and reduce byproducts. For example, Moderna, Inc. and BioNTech SE—both leaders in RNA therapeutics—have disclosed ongoing research into scalable circRNA manufacturing platforms, leveraging their established expertise in mRNA process development.
A major bottleneck remains the purification of circRNA from linear precursors and incomplete products. Companies are developing advanced chromatographic and electrophoretic methods to achieve the high purity required for clinical applications. TriLink BioTechnologies, a prominent supplier of custom RNA reagents, has announced investments in automated purification systems and analytical tools tailored for circRNA, aiming to support both preclinical and clinical manufacturing needs.
Another challenge is the development of robust quality control (QC) assays. CircRNA’s closed structure necessitates novel analytical approaches to confirm circularity, sequence integrity, and absence of immunogenic contaminants. Industry consortia and regulatory agencies are collaborating to establish standardized QC protocols, which are expected to be formalized over the next few years as more circRNA candidates enter clinical trials.
Looking ahead, the sector anticipates a shift toward modular, continuous manufacturing platforms, which promise greater flexibility and cost-efficiency. Companies such as Lonza Group AG and Cytiva are expanding their RNA manufacturing capabilities, including dedicated circRNA production suites and process development services. These investments are designed to address anticipated demand as circRNA therapeutics progress toward late-stage clinical development and eventual commercialization.
In summary, 2025 marks a pivotal year for manufacturing innovation in circRNA therapeutics. While technical and regulatory hurdles remain, the concerted efforts of leading biopharma companies and suppliers are expected to yield scalable, GMP-compliant solutions, paving the way for broader clinical adoption in the coming years.
Therapeutic Applications: Oncology, Rare Diseases, and Beyond
Circular RNA (circRNA) therapeutics are rapidly emerging as a novel class of RNA-based medicines, with significant momentum in oncology, rare diseases, and other therapeutic areas as of 2025. CircRNAs, characterized by their covalently closed loop structures, offer enhanced stability and translational efficiency compared to linear mRNA, making them attractive for therapeutic development.
In oncology, circRNA therapeutics are being explored for their potential to encode tumor-suppressing proteins, modulate immune responses, and serve as cancer vaccines. Orna Therapeutics, a pioneer in the field, has advanced its oRNA™ circular RNA platform into preclinical and early clinical development. In 2024, Orna announced the initiation of a first-in-human trial for ORN-101, a circRNA-based immunotherapy targeting solid tumors, in collaboration with Merck & Co., Inc. (known as MSD outside the US and Canada). This partnership, valued at over $3.5 billion in potential milestones, underscores the pharmaceutical industry’s confidence in circRNA’s therapeutic promise. The trial is expected to yield initial safety and efficacy data by late 2025, potentially setting the stage for broader clinical adoption.
Rare diseases represent another promising frontier. CircRNA’s ability to encode large and complex proteins positions it as a candidate for treating genetic disorders that are challenging for traditional gene therapies. Laronde, a company founded by Flagship Pioneering, is developing Endless RNA™ (eRNA), a proprietary circRNA platform. Laronde has disclosed preclinical progress in rare metabolic and genetic diseases, with plans to enter clinical trials in 2025. Their approach aims to provide durable protein expression with a single administration, potentially transforming the treatment landscape for conditions with high unmet need.
Beyond oncology and rare diseases, circRNA therapeutics are being investigated for infectious diseases, cardiovascular disorders, and regenerative medicine. The COVID-19 pandemic accelerated interest in RNA technologies, and circRNA-based vaccines are now in preclinical development by several companies, including Orna Therapeutics and Laronde. These vaccines aim to leverage circRNA’s stability for improved immunogenicity and longer-lasting protection.
Looking ahead, the next few years are expected to see a surge in clinical trial initiations, strategic partnerships, and potential early approvals, especially as manufacturing and delivery technologies mature. The field is also witnessing increased investment from major pharmaceutical companies, signaling confidence in circRNA’s potential to address previously intractable diseases. As 2025 unfolds, circRNA therapeutics are poised to transition from experimental platforms to tangible clinical solutions, with oncology and rare diseases at the forefront of this innovation wave.
Competitive Landscape and Intellectual Property Trends
The competitive landscape for circular RNA (circRNA) therapeutics is rapidly evolving as the field transitions from early discovery to preclinical and clinical development. As of 2025, several biotechnology companies and pharmaceutical giants are actively investing in circRNA platforms, aiming to leverage the unique stability, translational efficiency, and immunogenicity profile of circRNAs for therapeutic applications. The sector is characterized by a mix of established RNA therapeutics players expanding their modalities and a new wave of startups dedicated exclusively to circRNA technologies.
Among the most prominent companies, Orna Therapeutics stands out as a pioneer, having developed proprietary circular RNA expression systems (oRNA™) and secured significant funding and strategic partnerships. In 2023, Orna entered a collaboration with Merck & Co., Inc. (MSD) to develop novel vaccines and therapeutics using circRNA, with deal values reportedly exceeding $3.5 billion in potential milestones. Orna’s pipeline includes candidates for oncology and infectious diseases, with preclinical data demonstrating enhanced protein expression and durability compared to linear mRNA.
Another key player, Laronde, is advancing its Endless RNA™ (eRNA) platform, which utilizes engineered circRNAs for programmable protein expression. Laronde has raised over $400 million since its inception and is progressing multiple candidates toward IND-enabling studies, targeting rare diseases and immuno-oncology. The company’s approach is notable for its modularity and potential for redosable, non-integrating therapies.
The intellectual property (IP) landscape is becoming increasingly competitive, with a surge in patent filings related to circRNA synthesis, delivery, and modification technologies. Both Orna Therapeutics and Laronde have built substantial patent portfolios covering core aspects of circRNA design, manufacturing, and therapeutic use. Additionally, established RNA companies such as Moderna and BioNTech are exploring circRNA as a next-generation modality, filing patents and initiating early research programs.
Academic institutions and public research organizations are also contributing to the IP landscape, with technology transfer offices actively licensing circRNA-related inventions to industry partners. The next few years are expected to see increased patent disputes and cross-licensing agreements as more candidates enter clinical development and the boundaries of foundational IP are tested.
Looking ahead, the competitive intensity is likely to increase as additional companies enter the space and as the first clinical data from circRNA therapeutics become available. Strategic alliances, licensing deals, and M&A activity are anticipated, particularly as large pharmaceutical companies seek to secure access to enabling circRNA technologies. The sector’s trajectory will be shaped by the ability of innovators to demonstrate clinical efficacy, scalable manufacturing, and robust IP protection, setting the stage for circRNA to become a major pillar in the RNA therapeutics landscape by the late 2020s.
Investment, Funding, and M&A Activity
The investment landscape for circular RNA (circRNA) therapeutics has rapidly intensified in 2025, reflecting the sector’s maturation from early-stage research to translational and clinical development. Venture capital, strategic partnerships, and mergers and acquisitions (M&A) are all shaping the competitive dynamics as companies race to harness circRNA’s unique properties—such as enhanced stability and protein-coding potential—for next-generation therapies.
Several high-profile funding rounds have marked 2024 and early 2025. Orna Therapeutics, a pioneer in the field, closed a $221 million Series B round in 2023 and has since attracted additional strategic investments from major pharmaceutical players. Orna’s platform focuses on developing circular RNA-based vaccines and therapeutics, with a pipeline targeting oncology and rare diseases. The company’s collaboration with Merck & Co., Inc.—announced in 2022 and valued at up to $3.5 billion including upfront and milestone payments—remains one of the largest deals in the RNA therapeutics space, and is expected to yield clinical candidates in the next two years.
Another notable player, Laronde, has continued to expand its “Endless RNA” (eRNA) platform, raising over $440 million since its inception. Backed by Flagship Pioneering, Laronde is advancing a broad pipeline and has signaled intentions to enter clinical trials by 2025. The company’s approach has attracted interest from both investors and potential pharma partners, with ongoing discussions around co-development and licensing.
The sector is also witnessing increased M&A activity as established biopharma companies seek to secure access to circRNA technology. In late 2024, F. Hoffmann-La Roche Ltd announced the acquisition of a minority stake in a European circRNA startup, aiming to integrate the technology into its RNA therapeutics portfolio. Meanwhile, Moderna, Inc. has publicly stated its interest in expanding beyond mRNA and is rumored to be evaluating both partnerships and acquisitions in the circRNA space.
Looking ahead, the next few years are expected to see continued capital inflows, with a focus on companies demonstrating robust preclinical data and scalable manufacturing. Strategic alliances between circRNA innovators and large pharmaceutical firms are likely to accelerate, as the industry seeks to translate promising science into first-in-class therapeutics. The competitive landscape will be shaped by both the pace of clinical progress and the ability to secure intellectual property, manufacturing capabilities, and regulatory expertise.
Future Outlook: Opportunities, Risks, and Next-Generation Developments
The field of circular RNA (circRNA) therapeutics is poised for significant advances in 2025 and the following years, driven by a convergence of scientific breakthroughs, increased investment, and the maturation of enabling technologies. CircRNAs, characterized by their covalently closed loop structures, offer unique advantages over linear RNAs, including enhanced stability, reduced immunogenicity, and the potential for sustained protein expression. These properties have attracted the attention of both established biopharmaceutical companies and innovative startups, setting the stage for a new generation of RNA-based medicines.
Several companies are at the forefront of circRNA therapeutic development. Orna Therapeutics, a pioneer in the field, has advanced its proprietary oRNA™ technology platform to engineer synthetic circRNAs for in vivo protein expression. In 2023, Orna announced a strategic collaboration with Merck & Co., Inc. (MSD outside the US and Canada) to develop novel circRNA-based vaccines and therapeutics, with the potential for clinical candidates to enter trials as early as 2025. Similarly, Laronde is leveraging its Endless RNA™ (eRNA) platform to create programmable medicines, with a pipeline spanning rare diseases, oncology, and infectious diseases. Laronde’s manufacturing partnerships and expansion of its R&D facilities signal a commitment to advancing multiple candidates toward the clinic in the near term.
The opportunities for circRNA therapeutics are substantial. CircRNAs can be engineered to encode therapeutic proteins, modulate gene expression, or act as decoys for microRNAs, opening avenues in areas such as cancer immunotherapy, rare genetic disorders, and vaccine development. The durability and tunability of circRNA constructs may enable less frequent dosing and improved patient compliance compared to traditional mRNA therapies. Furthermore, the scalability of in vitro transcription and circularization processes is being addressed by technology providers and contract manufacturers, with companies like Evotec SE and Catalent, Inc. exploring capabilities to support clinical and commercial supply.
However, several risks and challenges remain. The immunogenicity profile of synthetic circRNAs in humans is not yet fully characterized, and off-target effects or unintended immune activation could pose safety concerns. Regulatory pathways for circRNA therapeutics are still evolving, requiring close engagement with agencies to define standards for quality, safety, and efficacy. Intellectual property landscapes are also complex, with foundational patents held by early movers.
Looking ahead, the next few years are expected to see the first clinical data from circRNA-based therapeutics, which will be pivotal in validating the platform’s promise. Advances in delivery technologies, such as lipid nanoparticles and tissue-specific targeting, will further expand the therapeutic reach of circRNAs. As the sector matures, strategic collaborations, robust manufacturing infrastructure, and regulatory clarity will be critical to realizing the full potential of circular RNA therapeutics.
Sources & References
